Targeted anti-BCR-ABL+ ALL therapy may benefit the heart
H. Kirchhoff, M. Ricke-Hoch, K. Wohlan, S. Pietzsch, U. Karsli, S. Erschow, R. Zweigerdt, A. Ganser, M. Eder, M. Scherr, D. Hilfiker-Kleiner
This paper shows that targeted therapies for BCR-ABL+ ALL can cause heart damage, but some treatments like dasatinib and venetoclax can reverse cardiac defects while others cannot.
bioRxiv · Jun 4, 2021 · PreprintCancer Biology